Roderick Clark, MD
Nephrology · Lafayette, LANPI 1225066939
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AstraZeneca at 27.5% of the total. That places this record below the midpoint for nephrology clinicians in LA, where the typical reported total is $1,900.
Across 53 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$285
- Amgen$184
- Mallinckrodt Hospital Products Inc.$126
- ANI Pharmaceuticals, Inc.$72
- Otsuka America Pharmaceutical, Inc.$66
- Calliditas Therapeutics US Inc.$60
- plus $243 from 8 others
Across 10 payments — averaging $3154.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$24K
- Akebia Therapeutics Inc$4K
- Boehringer Ingelheim Limited$2K
- AstraZeneca$750
What the payments were for
- Food & beverage$1,036100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 17 | $285 |
| Amgen | 9 | $184 |
| Mallinckrodt Hospital Products Inc. | 6 | $126 |
| ANI Pharmaceuticals, Inc. | 3 | $72 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Calliditas Therapeutics US Inc. | 3 | $60 |
| Akebia Therapeutics Inc | 2 | $55 |
| Novartis | 2 | $35 |
| Fresenius USA Marketing, Inc. | 2 | $33 |
| Lilly USA, LLC | 2 | $32 |
| Apellis Pharmaceuticals, Inc. | 1 | $30 |
| GSK | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $18 |
| Bayer | 1 | $16 |
How this compares
$1,036 in reported general payments places this provider in the 35th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 46 | $137,969 |
| AuryxiaFerric Citrate | 25 | $44,477 |
| LokelmaSodium Zirconium Cyclosilicate | 16 | $12,709 |
| Sevelamer Carbonate | 52 | $7,937 |
| Clonidine | 33 | $2,572 |
| Nifedipine ErNifedipine | 36 | $1,245 |
| Potassium Chloride | 45 | $703 |
| Clonidine Hcl | 41 | $566 |
| Cinacalcet Hcl | 16 | $559 |
| Amlodipine Besylate | 91 | $478 |
| Torsemide | 24 | $246 |
| Metolazone | 19 | $209 |
| Sodium ChlorideSodium Chloride 0.45 % | 12 | $153 |
| Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril | 14 | $132 |
| Hydrochlorothiazide | 38 | $129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $33 | $137,96946 claims |
| Akebia Therapeutics IncAuryxia | $55 | $44,47725 claims |
| AstraZenecaLokelma | $285 | $12,70916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 206 nephrology providers in Louisiana.
Other nephrology in Lafayette
- Anthony BlalockLafayette$350K
- Ziad AshkarLafayette$18K
- Akshey GuptaLafayette$6K
- Maximo LamarcheLafayette$5K
- Juan ZeikLafayette$5K
- Sreedhara AllaShreveport$722K
- Juan Carlos VelezNew Orleans$282K
- Jones SamuelBaton Rouge$207K
- Jon MaresCovington$103K
- Raja ZabanehShreveport$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.